June 13, 2024

Quoin Pharmaceuticals Cements Leadership Position in Rare Diseases with New Research Agreement

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company focused on rare and orphan diseases, announced a research agreement with The School of Pharmacy at University College Cork (UCC) in Ireland. This collaboration, aimed at developing innovative topical formulations of rapamycin (sirolimus), marks a strategic step towards potentially expanding the company’s treatment pipeline for a… [Read More]
June 13, 2024

Cardiol Therapeutics’ CardiolRx™ Demonstrates Marked Reduction in Pericarditis Pain

Clinical-stage life sciences company, Cardiol Therapeutics (Nasdaq: CRDL) has demonstrated a marked reduction in pericarditis pain in patients with symptomatic recurrent pericarditis treated with CardiolRx™. The company reported 8-week clinical data from its Phase 2 open-label MAvERIC-Pilot study evaluating CardiolRx™ in pericarditis, showing a substantial reduction in patient-reported pericarditis pain, as well as normalization of… [Read More]
June 13, 2024

EVgo, Inc. (EVGO) Reports Electrified Rideshare Growth as Q1 Commercial Throughput More Than Tripled

PRISM Emerging EV Index company and one of the nation’s largest public fast-charging networks for electric vehicles (EVs) EVgo Inc. (EVGO), saw significant growth in rideshare usage across its nationwide network, with commercial throughput more than tripling from Q1 2023 to Q1 2024. EVgo’s analysis revealed that the average rideshare driver charged about five times… [Read More]
June 13, 2024

Market Dynamics: S&P 500 Retreats as European Stocks Decline Amid Political Uncertainty

A downturn in market sentiment occurred as stocks retreated, driven by increasing political risks in France. The spread on France’s 10-year bonds over Germany’s surged to its widest since 2017, highlighting investor nervousness. This shift was precipitated by concerns over potential fiscal policy changes if Marine Le Pen’s National Rally party succeeds in the forthcoming… [Read More]
June 13, 2024

Counting Sheep: Six Companies Influencing our Sleep in 2024

SLEEP 2024, this year’s joint meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society, was held in Houston, TX from June 1-5. The conference welcomed more than 5,000 attendees, including physicians, researchers and sleep medicine specialists from more than 50 countries, and presentations and discussions centered around advances in sleep… [Read More]
June 13, 2024

Longeveron Completes Investigator Meeting in Pediatric Heart Trial, Shares Rise

Regenerative medicine company, Longeveron (Nasdaq: LGVN) topped the PRISM MarketView Global Health index on Wednesday after the company’s share price soared nearly 12% in morning trading. Longerveron announced this week the successful completion of an investigator meeting for ELPIS II, the company’s ongoing Phase 2b clinical trial evaluating Lomecel-B™ as a potential adjunct treatment for… [Read More]
June 12, 2024

PRISM NextGen Tech Leader Beamr Imaging (BMR) Up 22% on Oracle Cloud AI-Ready Video Solution Enabled by NVIDIA Computing

The leader in video optimization technology, Beamr Imaging (BMR) announced that its Beamr Cloud solution has achieved Powered by Expertise and is available in the Oracle Cloud Marketplace. The company is a member of Oracle PartnerNetwork (OPN) and its product is enabled by NVIDIA (NVDA) accelerated computing. Beamr provides value to this new solution via its… [Read More]
June 12, 2024

Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy

Shares in biotechnology company Capricor Therapeutics (Nasdaq: CAPR), rose on Tuesday after the company announced that it had successfully completed a Type-B meeting with the FDA regarding a Biologics License Application (BLA) submission for its lead asset, CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). Capricor also announced that the World Health Organization has… [Read More]
June 12, 2024

Sage Therapeutics Meets Primary Endpoint in Huntington’s Disease Trial

Sage Therapeutics (Nasdaq: SAGE) has announced positive topline results from its Phase 2 SURVEYOR study evaluating dalzanemdor (SAGE-718) as a treatment for Huntington’s Disease. The study met its primary endpoint, demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease… [Read More]